In the present study, we employed mass‐spectrometry‐based stable isotope‐resolved metabolomics (SIRM) with 13C515N2‐labeled‐glutamine to identify which specific metabolic pathways pancreatic tumors utilize upon GLS1 inhibition in vivo. Here, GLS is linked to pancreatic neoplasm.